Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Edema | 5 | 2022 | 7 | 2.810 |
Why?
|
| Uveitis | 8 | 2021 | 11 | 2.400 |
Why?
|
| Uveitis, Posterior | 3 | 2020 | 3 | 1.120 |
Why?
|
| Adalimumab | 3 | 2020 | 16 | 1.100 |
Why?
|
| Sirolimus | 3 | 2020 | 15 | 1.060 |
Why?
|
| Posterior Eye Segment | 2 | 2020 | 2 | 0.900 |
Why?
|
| Diabetic Retinopathy | 1 | 2022 | 5 | 0.900 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 138 | 0.790 |
Why?
|
| Intravitreal Injections | 6 | 2022 | 8 | 0.730 |
Why?
|
| Rituximab | 2 | 2019 | 53 | 0.720 |
Why?
|
| Immunologic Factors | 1 | 2019 | 39 | 0.680 |
Why?
|
| Rickettsia Infections | 1 | 2016 | 1 | 0.560 |
Why?
|
| Retinitis | 1 | 2016 | 3 | 0.560 |
Why?
|
| Eye Infections, Bacterial | 1 | 2016 | 5 | 0.560 |
Why?
|
| Tomography, Optical Coherence | 5 | 2021 | 16 | 0.540 |
Why?
|
| Glucocorticoids | 4 | 2022 | 67 | 0.510 |
Why?
|
| Triamcinolone Acetonide | 3 | 2021 | 6 | 0.460 |
Why?
|
| Visual Acuity | 5 | 2021 | 42 | 0.450 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 100 | 0.430 |
Why?
|
| Double-Blind Method | 4 | 2020 | 503 | 0.410 |
Why?
|
| Panuveitis | 2 | 2020 | 2 | 0.370 |
Why?
|
| Uveitis, Intermediate | 2 | 2020 | 2 | 0.370 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 132 | 0.360 |
Why?
|
| Humans | 20 | 2022 | 29337 | 0.350 |
Why?
|
| Treatment Outcome | 8 | 2021 | 3478 | 0.340 |
Why?
|
| Female | 10 | 2020 | 16197 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 437 | 0.250 |
Why?
|
| Middle Aged | 10 | 2020 | 9823 | 0.240 |
Why?
|
| Time Factors | 4 | 2020 | 1616 | 0.230 |
Why?
|
| Fluocinolone Acetonide | 1 | 2022 | 1 | 0.230 |
Why?
|
| Drug Implants | 1 | 2022 | 11 | 0.220 |
Why?
|
| Treatment Failure | 2 | 2020 | 159 | 0.220 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2021 | 1 | 0.210 |
Why?
|
| Strongylida Infections | 1 | 2021 | 1 | 0.210 |
Why?
|
| Retinal Detachment | 1 | 2021 | 6 | 0.210 |
Why?
|
| Electronic Health Records | 2 | 2019 | 66 | 0.200 |
Why?
|
| Retrospective Studies | 5 | 2022 | 3273 | 0.200 |
Why?
|
| Male | 10 | 2021 | 15621 | 0.200 |
Why?
|
| Intraocular Pressure | 1 | 2020 | 6 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1830 | 0.190 |
Why?
|
| Aged | 7 | 2020 | 9448 | 0.190 |
Why?
|
| Databases, Factual | 2 | 2019 | 330 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 162 | 0.180 |
Why?
|
| Uveitis, Anterior | 1 | 2019 | 4 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 100 | 0.180 |
Why?
|
| Spondylarthropathies | 1 | 2019 | 7 | 0.180 |
Why?
|
| Vision Disorders | 1 | 2019 | 23 | 0.170 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 340 | 0.170 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 23 | 0.170 |
Why?
|
| Adult | 7 | 2020 | 8601 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 142 | 0.160 |
Why?
|
| Prospective Studies | 1 | 2022 | 1811 | 0.150 |
Why?
|
| Retina | 1 | 2016 | 12 | 0.150 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 2 | 2008 | 2 | 0.150 |
Why?
|
| Rickettsia | 1 | 2016 | 1 | 0.140 |
Why?
|
| Chorioretinitis | 1 | 2016 | 3 | 0.140 |
Why?
|
| HLA-A Antigens | 1 | 2016 | 12 | 0.140 |
Why?
|
| Africa | 1 | 2016 | 10 | 0.140 |
Why?
|
| Travel | 1 | 2016 | 13 | 0.140 |
Why?
|
| Retinal Neoplasms | 1 | 2013 | 1 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 38 | 0.120 |
Why?
|
| Lymphoma | 1 | 2013 | 44 | 0.120 |
Why?
|
| Ocular Hypotension | 1 | 2012 | 1 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 218 | 0.100 |
Why?
|
| Eye Infections, Viral | 1 | 2008 | 2 | 0.080 |
Why?
|
| Drug Resistance, Viral | 1 | 2008 | 37 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 46 | 0.080 |
Why?
|
| Young Adult | 3 | 2020 | 1932 | 0.070 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2004 | 4 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 30 | 0.060 |
Why?
|
| Animals | 3 | 2021 | 4552 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 487 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4851 | 0.060 |
Why?
|
| Hawaii | 1 | 2021 | 3 | 0.050 |
Why?
|
| Magnolia | 1 | 2021 | 1 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2020 | 32 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 12 | 0.040 |
Why?
|
| Rats | 1 | 2021 | 854 | 0.040 |
Why?
|
| Computer Systems | 1 | 2018 | 5 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 30 | 0.040 |
Why?
|
| Adolescent | 2 | 2016 | 2279 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 521 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 553 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 324 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 840 | 0.040 |
Why?
|
| Chicago | 1 | 2019 | 865 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 175 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 788 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 226 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 208 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 389 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 495 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 2443 | 0.030 |
Why?
|
| Acyclovir | 1 | 2008 | 5 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2008 | 26 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 45 | 0.020 |
Why?
|
| Prednisone | 1 | 2008 | 67 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 241 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1113 | 0.020 |
Why?
|